Recombinant allergens

Citation
R. Valenta et D. Kraft, Recombinant allergens, PROG R RES, 31, 2001, pp. 195-200
Citations number
31
Categorie Soggetti
Current Book Contents
ISSN journal
14222140
Volume
31
Year of publication
2001
Pages
195 - 200
Database
ISI
SICI code
1422-2140(2001)31:<195:RA>2.0.ZU;2-C
Abstract
An increasing number of hypoallergenic allergen derivatives is currently be ing produced by genetic engineering as well as by synthetic peptide chemist ry and evaluated as candidate molecules for specific immunotherapy of type I allergy. One advantage of recombinant and synthetic hypoallergenic allerg en derivatives is that they can be designed to simultaneously retain the im munogenic/tolerogenic properties of the wild-type allergens and to exhibit a strongly reduced allergenic activity, When used for immunotherapy, it may be expected that hypoallergenic allergen derivatives will exhibit a lower rate of anaphylactic side effects. Furthermore, hypoallergenic allergen der ivatives can be used for component-resolved immunotherapy tailored accordin g to the individual patient's sensitization profile. This chapter summarize s strategies for the production and evaluation of recombinant as well as of synthetic hypoallergenic allergen derivatives as candidate vaccines for ty pe I allergy.